Clinical Responses to Tarlatamab Among Patients With Pulmonary Carcinoid.

INTRODUCTION

Pulmonary carcinoid (PC) is a rare, well-differentiated neuroendocrine tumor of the lung. In patients with metastatic disease, systemic therapies typically have low response rates, and long-term survival is poor. PC frequently expresses DLL3, but whether they respond to the DLL3-targeted bispecific T-cell engager tarlatamab is unknown.

METHODS

We analyzed 11 patients with DLL3-high PC treated with tarlatamab at the Memorial Sloan Kettering Cancer Center. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors version 1.1.

RESULTS

Response rate was eight of 11 (73%), including one patient with central nervous system-only disease, and the disease control rate was 11 of 11 (100%). All patients experienced a reduction in their measurable disease. One patient had progressed at the time of data cutoff, and the median progression-free survival was not reached. Cytokine release syndrome (CRS) occurred in cycle 1 in nine of 11 patients (82%), including two with grade 3 CRS.

CONCLUSIONS

Tarlatamab reported a high response rate in PC. CRS was common. Tarlatamab is a promising treatment option for patients with PC.